Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients with stage 3 (unresectable) o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Queirolo, Paola, Spagnolo, Francesco, Ascierto, Paolo Antonio, Simeone, Ester, Marchetti, Paolo, Scoppola, Alessandro, Del Vecchio, Michele, Di Guardo, Lorenza, Maio, Michele, Di Giacomo, Anna Maria, Antonuzzo, Andrea, Cognetti, Francesco, Ferraresi, Virginia, Ridolfi, Laura, Guidoboni, Massimo, Guida, Michele, Pigozzo, Jacopo, Chiarion Sileni, Vanna
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2014
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023079/
https://ncbi.nlm.nih.gov/pubmed/24532241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1400-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars